Vice President for Strategic Partnerships Expands Exco InTouch’s Global Reach
News Feb 26, 2016
Exco InTouch’s Valued Partner Network provides extensive support to Clinical Research Organizations (CROs) and technology service providers by integrating market leading patient engagement and electronic Clinical Outcome Assessment (eCOA) capabilities into their existing service portfolios. This key initiative for Exco InTouch is headed up by Martin Cook - Vice President for Strategic Partnerships, whose established experience and in-depth understanding of both the clinical technology and CRO markets make him ideally placed to provide the dedicated support these organizations require.
As Martin explains: “It is a very exciting time for CROs right now since we know that half of Phase II and Phase III trials are being outsourced by pharmaceutical and biotechnology companies to CROs. By working alongside our CRO and Technology clients on partner strategy, value generation and program development we are able to ensure that they are in the strongest position to take advantage of the growth opportunities patient engagement is presenting to them.”
Exco InTouch provides dedicated resource and custom support to meet the specific needs of each valued partner; providing preferred flexible pricing, master services agreements, operational and strategic business support. Partners are able to take advantage of industry expertise across the spectrum of Exco InTouch patient engagement and data capture services.
Martin continues “We have put a real focus on providing our partners with unrivalled products and the highest quality service levels. Having successfully achieved this for our existing clients we are now seeking to engage new organizations around the globe to join our Valued Partner Network.”
Cannabinoids Are Easier on the Brain Than Booze, Study FindsNews
The research was published in the journal Addiction.READ MORE
Compound Prevents Neurological Damage, Shows Cognitive Benefits in Mouse model of Alzheimer’s DiseaseNews
Mouse nicotinamide riboside study shows potential for human research.READ MORE